Dose-finding Study of MT-1303

Exclusion Criteria

• •Primary progressive, secondary progressive or progressive relapsing MS at screening
• •Disease duration \>15 years combined with an EDSS score ≤2.0
• •Relapse of MS during the Screening Period
• •History or known presence of other neurological disorders likely to render the subject unsuitable for the study
• •History of any of a list of pre-defined cardiovascular diseases
• •History or known presence of any significant central nervous system, infectious, metabolic, oncological, ophthalmological or respiratory system disease or illness likely to render the subject unsuitable for the study
• •Previous exposure to any sphingosine 1-phosphate receptor modulator
• •Receipt of a live vaccine or systemic corticosteroid use within 28 days prior to randomisation
• •Previous treatment with beta-interferons or glatiramer acetate within 14 days prior to randomisation
• •Previous treatment with intravenous immunoglobulin, plasmapheresis, certain immunosuppressants, lymphocyte-depleting therapy, total body irradiation or bone marrow transplantation
• •Need, or likely need for, treatment with Class I or III anti-arrhythmic drugs or with heart-rate-lowering beta-blockers or calcium-channel blockers, or with any other drugs which can reduce the heart rate
• •Evidence of significant anaemia, thrombocytopenia, leucopoenia or lymphocytopenia, renal or hepatic impairment
• •Clinically significant electrocardiogram (ECG) findings.